Application of miRNA (micro Ribonucleic Acid) in preparation of product for diagnosing drug resistance of lung cancer

Through the detection of miRNAs such as miR-1207-5p, miR-1915-3p, miR-718, combined with miR-4725-5p, the problem of screening for cisplatin chemotherapy resistance in lung cancer patients is solved, and a cost-effective Diagnostic methods improve treatment sensitivity and monitoring feasibility, reducing diagnostic impairment and cost.

CN119082299APending Publication Date: 2024-12-06THE CENTRAL HOSPITAL OF WUHAN (WUHAN NO 2 HOSPITAL WUHAN CANCER RESEARCH INSTITUTE)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410952964.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-16
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The prior art is difficult to effectively screen and diagnose the resistance of lung cancer patients to cisplatin chemotherapy, resulting in poor treatment effects, and traditional diagnostic methods have great damage to patients and are costly.

Method used

MiRNAs such as miR-1207-5p, miR-1915-3p, miR-718 are used as biomarkers. By designing specific primers and detection kits, quantitative detection of relative expression levels is carried out for lung cancer drug resistance diagnosis, combined with miR -4725-5p as a joint detection indicator provides a cost-effective diagnostic method.

Benefits of technology

It realizes early rapid judgment of cisplatin resistance in lung cancer patients, improves treatment sensitivity and monitoring feasibility, reduces diagnostic damage and cost, and avoids the loss of the optimal treatment window caused by drug resistance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention provides an application of miRNA (micro Ribonucleic Acid) in preparation of a product for diagnosing drug resistance of lung cancer. The miRNA is selected from at least one of miR-1207-5p, miR-1915-3p and miR-718. The invention discovers that miR-1207-5p, miR-1915-3p and miR-718 are closely related to lung cancer chemotherapy drug resistance for the first time, the expression levels of miR-1207-5p, miR-1915-3p and miR-718 in drug-resistant lung cancer patients and non-drug-resistant lung cancer patients are remarkably different, and the expression levels of miR-1207-5p, miR-1915-3p and miR-718 in lung cancer cis-platinum-resistant cells and non-drug-resistant cells are also remarkably different. Based on the three miRNAs and the known miR-4725-5p as joint detection indexes, the kit can be used for diagnosing the drug resistance sensitivity of lung cancer patients so as to guide the lung cancer patients to accurately take drugs, and has a very good application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of molecular biology, and in particular to a biomarker for lung cancer drug resistance diagnosis, and in particular to a use of miRNA in the preparation of a product for lung cancer drug resistance diagnosis. Background Art

[0002] At present, the most commonly used treatment for lung cancer is surgery combined with chemotherapy. Commonly used chemotherapy drugs include cis-Dichlorodiamine-platinum (DDP) and taxanes. Among them, DDP inhibits the synthesis and repair of tumor cell DNA by targeting DNA and topoisomerase II (type II topoisomerase, Topo II), induces cell apoptosis, and achieves the effect of inhibiting tumor cell growth. Platinum-based chemotherapy can improve the cure rate in the early stage of non-small cell lung cancer and prolong the survival period in the late stage. However, once drug resistance occurs, it is difficult to achieve satisfactory treatment effects. The DDP resistance rate of lung cancer patients is 63%, which seriously affects the prognosis and quality of life of patients. Therefore, exploring the biomarkers of cisplatin resistance in lung cancer and developing new diagnostic test kits for cisplatin resistance can screen cisplatin resistance in lung cancer to guide clinical drug adjustments.

[0003] Traditional diagnosis of lung cancer requires the use of bronchoscopic biopsy, sputum to search for tumor cells, pleural effusion to search for tumor cells, lung puncture biopsy, thoracoscopic lung biopsy, mediastinal or superficial lymph node biopsy, chest X-ray (X-ray examination) and other methods. These examination methods are very harmful to patients and have high economic costs.

[0004] miRNAs are a class of endogenous non-protein-coding microRNAs, generally 18-24 nucleotides in length, which can regulate gene expression at the transcriptional level by binding to the complementary sequence of the target mRNA, leading to the degradation of the target mRNA or gene silencing. miRNAs play an important regulatory role in tumor cell proliferation, anti-apoptosis, migration and invasion, and the response of tumor cells to drug treatment.

[0005] Inventor Zhang Yibin's previous research found that miR-4725-5p is highly expressed in the plasma and cell lines of lung cancer patients, and may promote the proliferation, migration and resistance to cisplatin treatment of lung cancer cells by regulating the expression of the target gene CDH1 (Zhang Yibin. Study on the mechanism of miR-4725-5p targeted inhibition of CDH1 to regulate lung cancer proliferation, migration and cisplatin resistance [D]. Hubei University of Chinese Medicine, 2022. DOI: 10.27134 / d.cnki.ghbzc.2022.000128.).

[0006] The above previous study preliminarily explored the molecular mechanism of miR-4725-5p in lung cancer cells and found that CDH1 is a potential target gene of miR-4725-5p. MiR-4725-5p has two binding sites in the 3'UTR region of CDH1. E-cadherin is missing or significantly downregulated in highly invasive and metastatic tumor cells. Overexpression of miR-4725-5p can significantly downregulate the protein expression level of E-cadherin, which may be one of the molecular mechanisms by which miR-4725-5p promotes lung cancer cell migration and cisplatin resistance. However, E-cadherin is also regulated by signaling pathways such as PI3K and MAPK. Whether miR-4725-5p regulates the protein expression of E-cadherin in lung cancer cells by directly targeting CDH1 needs to be further verified by reporter gene experiments. In other words, although the study preliminarily reported the molecular mechanism of miR-4725-5p in lung cancer cells, it was not comprehensive in predicting lung cancer proliferation, metastasis or cisplatin resistance. It did not further verify whether there were other mechanisms, such as other miRNAs that also affect lung cancer proliferation, metastasis or cisplatin resistance, that is, a single marker test may have false positives. In addition, the above literature did not report the specific primers corresponding to miR-4725-5p.

[0007] Therefore, there is an urgent need to find a diagnostic marker for cisplatin resistance with high cost-effectiveness and stability, design corresponding specific primers, and develop a diagnostic kit for the diagnosis of cisplatin resistance, so as to be able to quickly and clinically determine that patients may develop drug tolerance, thereby providing guidance and adjustments for clinical medication to avoid drug resistance and delay the patient's optimal treatment window. Summary of the invention

[0008] In view of this, the present application proposes the use of miRNA in the preparation of a product for diagnosing lung cancer resistance.

[0009] The purpose of the present invention is achieved through the following technical solutions:

[0010] In a first aspect, the present application provides a use of a miRNA detection reagent in the preparation of a product for diagnosing lung cancer drug resistance, characterized in that the miRNA is selected from at least one of miR-1207-5p, miR-1915-3p, and miR-718.

[0011] In the present invention, the existing detection reagents of miR-1207-5p, miR-1915-3p, and miR-718 can be used for the diagnosis of lung cancer resistance, and the detection reagents prepared by the independently designed primer group can also be used for the diagnosis of lung cancer resistance, with the premise of being able to achieve quantitative detection of the relative expression levels of miR-1207-5p, miR-1915-3p, and miR-718.

[0012] As a preferred embodiment, the miRNA is selected from any one of miR-1207-5p, miR-1915-3p, and miR-718, or is selected from any one of the combinations of miR-1207-5p and miR-1915-3p, the combinations of miR-1207-5p and miR-718, the combinations of miR-1915-3p and miR-718, and the combinations of miR-1207-5p, miR-1915-3p, and miR-718. As a preferred embodiment, the detection reagent of the miRNA includes a primer set for the miRNA, and the primer set includes a stem-loop structure reverse transcription primer, a PCR upstream primer, and a PCR downstream primer.

[0013] As a further preferred embodiment, the primer set includes at least one of the following groups:

[0014] (1) Stem-loop structure reverse transcription primer, PCR upstream primer and PCR downstream primer for miR-1207-5p, the nucleotide sequences of which are shown in SEQ ID NOs. 1 to 3;

[0015] (2) Stem-loop structure reverse transcription primer, PCR upstream primer and PCR downstream primer for miR-1915-3p, the nucleotide sequences of which are shown in SEQ ID NOs. 4 to 6;

[0016] (3) The stem-loop structure reverse transcription primer, PCR upstream primer and PCR downstream primer for miR-718, the nucleotide sequences are shown in SEQ ID NOs. 7 to 9.

[0017] As a preferred embodiment, the lung cancer resistance is lung cancer resistance caused by platinum-based chemotherapy.

[0018] As a further preferred embodiment, the platinum drug is at least one selected from cisplatin, carboplatin, nedaplatin, oxaliplatin, and lobaplatin; more preferably, it is cisplatin.

[0019] As a preferred embodiment, the diagnostic product includes any one of a diagnostic kit and a diagnostic chip.

[0020] In a second aspect, the present application provides a use of a miRNA detection reagent in the preparation of a product for diagnosing lung cancer resistance, wherein the miRNA includes miR-4725-5p and at least one of miR-1207-5p, miR-1915-3p, and miR-718.

[0021] As a preferred embodiment, the miRNA is selected from any group consisting of a combination of miR-4725-5p and miR-1207-5p, a combination of miR-4725-5p and miR-1915-3p, a combination of miR-4725-5p and miR-718, a combination of miR-4725-5p and miR-1207-5p and miR-1915-3p, a combination of miR-4725-5p and miR-1207-5p and miR-718, a combination of miR-4725-5p and miR-1915-3p and miR-718, and a combination of miR-4725-5p and miR-1207-5p, miR-1915-3p and miR-718.

[0022] As a further preferred embodiment, the miRNA is a combination of miR-4725-5p and miR-1207-5p, miR-1915-3p, and miR-718.

[0023] As a preferred embodiment, the miRNA detection reagent comprises: a stem-loop structure reverse transcription primer, a PCR upstream primer and a PCR downstream primer for miR-4725-5p, the nucleotide sequences of which are shown in SEQ ID NOs. 10 to 12;

[0024] And at least one of the following groups:

[0025] (1) Stem-loop structure reverse transcription primer, PCR upstream primer and PCR downstream primer for miR-1207-5p, the nucleotide sequences of which are shown in SEQ ID NOs. 1 to 3;

[0026] (2) Stem-loop structure reverse transcription primer, PCR upstream primer and PCR downstream primer for miR-1915-3p, the nucleotide sequences of which are shown in SEQ ID NOs. 4 to 6;

[0027] (3) The stem-loop structure reverse transcription primer, PCR upstream primer and PCR downstream primer for miR-718, the nucleotide sequences are shown in SEQ ID NOs. 7 to 9.

[0028] As a further preferred embodiment, the miRNA detection reagent comprises: a stem-loop structure reverse transcription primer, a PCR upstream primer and a PCR downstream primer for miR-4725-5p, the nucleotide sequences of which are shown in SEQ ID NOs. 10 to 12;

[0029] Stem-loop structure reverse transcription primer, PCR upstream primer and PCR downstream primer for miR-1207-5p, the nucleotide sequences are shown in SEQ ID NOs. 1 to 3;

[0030] Stem-loop structure reverse transcription primer, PCR upstream primer and PCR downstream primer for miR-1915-3p, the nucleotide sequences are shown in SEQ ID NOs. 4 to 6;

[0031] The nucleotide sequences of the stem-loop structure reverse transcription primer, PCR upstream primer and PCR downstream primer for miR-718 are shown in SEQ ID NOs. 7 to 9.

[0032] In a third aspect, the present application provides a primer combination, characterized in that it includes at least one of the following groups:

[0033] (1) a stem-loop structure reverse transcription primer, a PCR upstream primer, and a PCR downstream primer for amplifying miR-1207-5p, the nucleotide sequences of which are shown in SEQ ID NOs. 1 to 3;

[0034] (2) a stem-loop structure reverse transcription primer, a PCR upstream primer, and a PCR downstream primer for amplifying miR-1915-3p, the nucleotide sequences of which are shown in SEQ ID NOs. 4 to 6;

[0035] (3) a stem-loop structure reverse transcription primer, a PCR upstream primer, and a PCR downstream primer for amplifying miR-718, the nucleotide sequences of which are shown in SEQ ID NOs. 7 to 9;

[0036] (4) The stem-loop structure reverse transcription primer, PCR upstream primer and PCR downstream primer used to amplify miR-4725-5p, the nucleotide sequences of which are shown in SEQ ID NOs. 10 to 12.

[0037] In a fourth aspect, the present application provides a miRNA detection reagent, characterized in that it comprises the primer combination described in claim 9.

[0038] As a preferred embodiment, the detection reagent further comprises reverse transcriptase, buffer, DNA polymerase and dNTP.

[0039] In a fifth aspect, the present application provides a detection method based on the aforementioned miRNA detection reagent, comprising the following steps: extracting RNA from the sample, performing a reverse transcription reaction to reverse transcribe the RNA into cDNA, and then performing real-time fluorescence quantitative PCR on the cDNA to obtain the relative expression level of the miRNA.

[0040] As a preferred embodiment, the sample includes any one of a plasma sample and a cell sample.

[0041] In a sixth aspect, the present application provides a lung cancer resistance diagnosis kit, comprising the aforementioned miRNA detection reagent.

[0042] Compared with the prior art, the present invention has the following beneficial effects:

[0043] 1) The present invention discovered for the first time that miR-1207-5p, miR-1915-3p and miR-718 are closely related to chemotherapy resistance in lung cancer, and their expression levels in patients with resistant lung cancer and those with inresistant lung cancer showed significant differences (p<0.05). Cell experiments further verified that the expression levels of miR-1207-5p, miR-1915-3p and miR-718 in cisplatin-resistant lung cancer cells A549 / DDP and inresistant lung cancer cells A549 also showed significant differences (p<0.0001).

[0044] 2) The present invention uses miR-1207-5p, miR-1915-3p, miR-718 and miR-4725-5p as joint detection indicators, and the AUC obtained by the ROC curve is 0.910, the sensitivity is 82.32%, and the specificity is 90.1%, which proves the feasibility of using miR-1207-5p, miR-1915-3p and miR-718 as joint detection indicators for diagnosing the drug resistance sensitivity of lung cancer patients and monitoring during cisplatin treatment to guide clinical medication. In addition, the examination of plasma is less harmful to patients than methods such as bronchoscopic biopsy and has great economic benefits.

[0045] 3) The present invention also conducted a cell resistance experiment on A549 / DDP and A549 cells and found that overexpression of miR-1207-5p, miR-1915-3p and miR-718 could change the sensitivity of A549 / DDP cells and A549 cells to cisplatin. BRIEF DESCRIPTION OF THE DRAWINGS

[0046] Figure 1 is the expression levels of miR-1207-5p, miR-1915-3p, and miR-718 in patients with chemotherapy-resistant lung cancer and patients with chemotherapy-inresistant lung cancer;

[0047] Figure 2The expression levels of miR-1207-5p, miR-1915-3p and miR-718 in A549 / DDP and A549 cells. DETAILED DESCRIPTION

[0048] The present invention is described below with reference to specific examples. It will be appreciated by those skilled in the art that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention in any way.

[0049] For any terms not specifically explained or described in this application text, please refer to the textbooks related to medicinal chemistry, organic chemistry, biochemistry, and pharmacology.

[0050] Based on previous studies, the inventors further explored the expression levels of the other 7 miRNAs in the plasma of patients with chemotherapy-resistant and chemotherapy-sensitive lung cancer, as well as in the cisplatin-resistant cell line A549 / DDP of lung cancer and the non-resistant cell line A549 of lung cancer, and conducted cell resistance experiments on A549 / DDP and A549 cells. The experimental results showed that in addition to miR-4725-5p, there were 3 other miRNAs that were highly expressed in the plasma of patients with cisplatin-resistant lung cancer and in the cisplatin-resistant cell line A549 / DDP of lung cancer. Through cell resistance experiments on A549 / DDP and A549 cells, it was found that overexpression of these 4 miRNAs could change the sensitivity of A549 / DDP cells and A549 cells to cisplatin. Furthermore, the inventors designed specific primers for the above four miRNAs. By only jointly detecting miR-1207-5p, miR-1915-3p, miR-718, and miR-4725-5p in the plasma of lung cancer patients, cisplatin resistance in lung cancer can be screened and diagnosed. In this way, it is possible to quickly and clinically determine that patients may develop drug resistance at an early stage, thereby providing guidance and adjustments for clinical medication to avoid drug resistance and delay the patient's optimal treatment window.

[0051] The following will be described in detail with reference to the examples. The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental raw materials, reagent materials, strains, detection kits, etc. used in the following examples are all commercially available products unless otherwise specified.

[0052] The nucleotide sequences of the miRNAs involved in the following examples are as follows:

[0053] miR-1207-5p sequence: 5'UGGCAGGGAGGCUGGGAGGGG 3' (SEQ ID NO.25)

[0054] miR-1915-3p sequence: 5'CCCCAGGGCGACGGCGGCGGG 3' (SEQ ID NO.26)

[0055] miR-718 sequence: 5'CUUCCGCCCCGCCGGGCGUCG 3' (SEQ ID NO.27)

[0056] miR-6740-5p sequence: 5'AGUUUGGGAUGGAGAGAGGAGA 3' (SEQ ID NO.28)

[0057] miR-6826-5p sequence: 5'UCAAUAGGAAAGAGGUGGGACCU 3' (SEQ ID NO.29)

[0058] miR-5703 sequence: 5'AGGAGAAGUCGGGAAGGU 3' (SEQ ID NO.30)

[0059] miR-642b-3p sequence: 5'AGACACAUUUGGAGAGGGACCC 3' (SEQ ID NO.31)

[0060] miR-4725-5p sequence: 5'AGACCCUGCAGCCUUCCCACC 3' (SEQ ID NO.32)

[0061] Example 1

[0062] Based on the previous experiments, we used chips to screen 7 miRNAs that are abnormally expressed in lung cancer, namely miR-6740-5p, miR-6826-5p, miR-718, miR-5703, miR-1207-5p, miR-642b-3p, and miR-1915-3p. To further study the role of these 7 miRNAs in the mechanism of chemotherapy resistance in lung cancer, we verified them in the plasma of lung cancer patients. The specific steps are as follows:

[0063] 1. Collect samples

[0064] Plasma samples from 82 lung cancer patients (blood routine specimens after examination from the Laboratory Department of Wuhan Central Hospital) were collected. According to the sensitivity of lung cancer patients to chemotherapy treatments such as cisplatin, they were divided into two groups: chemotherapy-resistant and chemotherapy-sensitive (inresistant) lung cancer. There were 26 resistant patients and 56 inresistant patients.

[0065] 2. Extraction of Plasma RNA

[0066] (1) Take out the plasma previously frozen at -80°C in advance and place it on ice to thaw.

[0067] (2) Mix the thawed plasma by inverting it upside down. Take 300 μL of plasma and add 300 μL of Trizol. Vortex to mix well and let it stand at room temperature for 15 min.

[0068] (3) Add 120 μL of chloroform, mix by inverting, let stand for 5 min, and centrifuge at 4°C, 12,000 rpm for 15 min.

[0069] (4) After centrifugation, the solution was separated into layers. About 300 μL of the upper aqueous phase was drawn into a new EP tube. 300 μL of isopropanol was added, and the mixture was mixed by inversion. The mixture was placed in a -20°C refrigerator for 30 min. Centrifuged at 4°C, 12,000 rpm, for 15 min, and the supernatant was discarded.

[0070] (5) Add 1 mL of freshly prepared, pre-cooled 75% ethanol to the precipitate to wash the RNA.

[0071] (6) Centrifuge at 4°C, 12,000 rpm for 5 min and discard the supernatant. Centrifuge again for 1 min under the same conditions and discard the residual liquid.

[0072] (7) Open the cap of the EP tube with the precipitate and place it at room temperature for 5 minutes to dry to allow the ethanol to evaporate completely.

[0073] (8) Add 25 μL DEPC water to dissolve RNA for subsequent experiments.

[0074] 3. Reverse Transcription

[0075] The extracted RNA was reverse transcribed into cDNA using a reverse transcription kit from Nanjing Vazyme Company.

[0076] (1) The reverse transcription system is as follows:

[0077]

[0078] Prepare the reagents according to the above system, mix them evenly, and centrifuge them instantly.

[0079] The nucleotide sequence of the stem-loop structure reverse transcription primer used is shown in Table 1.

[0080] (2) Perform reverse transcription using an ABI step one plus PCR instrument, setting the program to 37°C, 15 min; 85°C, 5 sec.

[0081] 4. Real-time fluorescence quantitative PCR

[0082] (1) Use the q-RTPCR kit from Nanjing Vazyme Company. The reaction system is as follows:

[0083]

[0084] The reagents were prepared according to the above system.

[0085] The nucleotide sequences of the upstream primer and the downstream primer used are shown in Table 1.

[0086] Table 1

[0087]

[0088]

[0089] (2) Use ABI step one plus PCR instrument for detection: pre-denaturation at 95°C for 30 sec, 95°C for 10 sec, 60°C for 30 sec, 40 cycles, and collect melting curve at 60°C for 60 sec, 95°C for 15 sec.

[0090] (3) According to the CT value, 2 -△Ct To calculate the relative expression of each target miRNA, 2 -△△Ct The relative expression level of each miRNA was calculated.

[0091] 5. Statistical Analysis of Results

[0092] All statistical analyses and graphs were prepared using Graphpad Prism 6 software. The results between the two groups were compared using the Mann–Whitney U test. Each group of experiments was repeated at least three times. When p < 0.05, the difference was statistically significant, indicated by *, when p < 0.01, it was indicated by **, and when p < 0.001, it was indicated by ***.

[0093] The expression levels of 7 miRNAs abnormally expressed in lung cancer (miR-6740-5p, miR-6826-5p, miR-718, miR-5703, miR-1207-5p, miR-642b-3p, miR-1915-3p) in the plasma of 26 chemotherapy-resistant and 56 chemotherapy-sensitive (inresistant) lung cancer patients were analyzed. The results showed that the expression levels of miR-1207-5p, miR-1915-3p and miR-718 in chemotherapy-resistant lung cancer patients (Drug resistance) and chemotherapy-inresistant lung cancer patients (Drug sensitivity) showed significant differences (such as Figure 1As shown, p<0.05), while the expression levels of miR-6740-5p, miR-6826-5p, miR-5703 and miR-642b-3p in patients with chemotherapy-resistant lung cancer and patients with chemotherapy-inresistant lung cancer were not significantly different. This result shows that miR-1207-5p, miR-1915-3p and miR-718 are closely related to chemotherapy resistance in lung cancer.

[0094] Example 2

[0095] To further verify the correlation between miR-1207-5p, miR-1915-3p, and miR-718 and chemotherapy resistance in lung cancer, we analyzed the expression of these three miRNAs in cisplatin-resistant lung cancer cells A549 / DDP (purchased from Wuhan Pronocell Life Science Co., Ltd.) and non-resistant lung cancer cells A549 (purchased from Shanghai Meixuan Biotechnology Co., Ltd.). The specific steps are as follows:

[0096] 1. Extraction of Cellular RNA

[0097] The cultured A549 / DDP and A549 cells were produced by Nanjing Vazyme Company. RNA was extracted using the Cell / Tissue Total RNA Isolation Kit V2.

[0098] (1) Digest the cells with 0.25% trypsin. After digestion, centrifuge to obtain the cell pellet. Add 500 μL of Buffer RL to the pellet, mix well, and vortex for 5 to 6 seconds.

[0099] (2) Transfer the liquid to FastPure gDNA-Filter Column III and centrifuge at 25°C, 12,000 rpm for 1 min to remove genomic DNA.

[0100] (3) Collect the above centrifuged solution, add 250 μL of anhydrous ethanol, and mix well.

[0101] (4) Transfer the mixed solution into the RNA adsorption column FastPure RNA Column III, centrifuge at 25°C, 12,000 rpm for 1 min, and discard the filtrate.

[0102] (5) Add 700 μL Buffer RW1 to FastPure RNA Column III, centrifuge at 25°C, 12,000 rpm for 1 min, and discard the filtrate.

[0103] (6) Add 700 μL Buffer RW2 to FastPure RNA Column III, centrifuge at 25°C, 12,000 rpm for 1 min, and discard the filtrate.

[0104] (7) Add 500 μL Buffer RW2 to FastPure RNA Column III, centrifuge at 25°C, 12,000 rpm for 2 min, and discard the filtrate.

[0105] (8) Remove the adsorption column and transfer it to a new RNase-free Collection Tubes 1.5mL centrifuge tube. Add 20μL RNase-free ddH2O to the surface of the adsorption membrane. Let it stand at room temperature for 2-3 minutes. Centrifuge at 12000rpm for 1 minute. The product obtained after centrifugation is the total cellular RNA.

[0106] 2. Reverse Transcription

[0107] The method is the same as in Example 1.

[0108] 3. Real-time fluorescence quantitative PCR

[0109] The method is the same as in Example 1.

[0110] 4. Statistical Analysis of Results

[0111] All statistical analyses and graphs were prepared using Graphpad Prism 6 software. The results between the two groups were compared using the Mann–Whitney U test. Each group of experiments was repeated at least three times. When p < 0.05, the difference was statistically significant, indicated by *, when p < 0.01, it was indicated by **, and when p < 0.001, it was indicated by ***.

[0112] The expression levels of miR-1207-5p, miR-1915-3p, and miR-718 in A549 / DDP and A549 cells were shown in Figure 2 As shown by Figure 2 The results showed that the expression levels of miR-1207-5p, miR-1915-3p and miR-718 in A549 / DDP and A549 cells showed significant differences (p<0.0001). This result further confirmed that miR-1207-5p, miR-1915-3p and miR-718 are closely related to chemotherapy resistance in lung cancer and can be used as biomarkers for the diagnosis of chemotherapy resistance sensitivity in patients with lung cancer.

[0113] Using miR-1207-5p, miR-1915-3p, miR-718 and miR-4725-5P as joint diagnostic indicators, the AUC value obtained by ROC curve was 0.910, the sensitivity was 82.32%, and the specificity was 90.1%. This proves the feasibility of using miR-1207-5p, miR-1915-3p and miR-718 as joint detection indicators for diagnosing drug resistance sensitivity of lung cancer patients and monitoring during cisplatin treatment, so as to guide clinical medication.

[0114] The specific embodiments described above further illustrate the objectives, technical solutions and beneficial effects of the present invention in detail. It should be understood that the above are only specific embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of this application should be included in the protection scope of this application.

Claims

1. Use of a miRNA detection reagent in the preparation of a product for lung cancer drug resistance diagnosis, It is characterized in that The miRNA is selected from at least one of miR-1207-5p, miR-1915-3p, and miR-718.

2. The use according to claim 1, It is characterized in that The miRNA detection reagent comprises a primer set for miRNA, wherein the primer set comprises a stem-loop structure reverse transcription primer, a PCR upstream primer and a PCR downstream primer; or The lung cancer drug resistance is lung cancer drug resistance caused by platinum-based chemotherapy. Preferably, the platinum-based drug is selected from at least one of cisplatin, carboplatin, nedaplatin, oxaliplatin and lobaplatin. More preferably, the platinum-based drug is cisplatin; or The diagnostic product includes any one of a diagnostic kit and a diagnostic chip.

3. The use according to claim 2, It is characterized in that The primer set includes at least one of the following groups: (1) Stem-loop structure reverse transcription primer, PCR upstream primer and PCR downstream primer for miR-1207-5p, the nucleotide sequences of which are shown in SEQ ID NOs. 1 to 3; (2) Stem-loop structure reverse transcription primer, PCR upstream primer and PCR downstream primer for miR-1915-3p, the nucleotide sequences of which are shown in SEQ ID NOs. 4 to 6; (3) The stem-loop structure reverse transcription primer, PCR upstream primer and PCR downstream primer for miR-718, the nucleotide sequences are shown in SEQ ID NOs. 7 to 9.

4. Use of a miRNA detection reagent in the preparation of a product for lung cancer drug resistance diagnosis, It is characterized in that The miRNA includes miR-4725-5p and at least one of miR-1207-5p, miR-1915-3p and miR-718.

5. The use according to claim 4, It is characterized in that The miRNA detection reagent includes: a stem-loop structure reverse transcription primer for miR-4725-5p, a PCR upstream primer and a PCR downstream primer, and the nucleotide sequence is shown in SEQ ID NO.10-12; And at least one of the following groups: (1) Stem-loop structure reverse transcription primer, PCR upstream primer and PCR downstream primer for miR-1207-5p, the nucleotide sequences of which are shown in SEQ ID NOs. 1 to 3; (2) Stem-loop structure reverse transcription primer, PCR upstream primer and PCR downstream primer for miR-1915-3p, the nucleotide sequences of which are shown in SEQ ID NOs. 4 to 6; (3) The stem-loop structure reverse transcription primer, PCR upstream primer and PCR downstream primer for miR-718, the nucleotide sequences are shown in SEQ ID NOs. 7 to 9.

6. A primer combination, It is characterized in that Include at least one of the following groups: (1) a stem-loop structure reverse transcription primer, a PCR upstream primer, and a PCR downstream primer for amplifying miR-1207-5p, the nucleotide sequences of which are shown in SEQ ID NOs. 1 to 3; 一种对肺癌顺铂耐药筛查的引物组合物及其医药用途 Claims (2) a stem-loop structure reverse transcription primer, a PCR upstream primer, and a PCR downstream primer for amplifying miR-1915-3p, the nucleotide sequences of which are shown in SEQ ID NOs. 4 to 6; (3) a stem-loop structure reverse transcription primer, a PCR upstream primer, and a PCR downstream primer for amplifying miR-718, the nucleotide sequences of which are shown in SEQ ID NOs. 7 to 9; (4) The stem-loop structure reverse transcription primer, PCR upstream primer and PCR downstream primer used to amplify miR-4725-5p, the nucleotide sequences of which are shown in SEQ ID NOs. 10 to 12.

7. A miRNA detection reagent, It is characterized in that Comprising the primer combination described in claim 6.

8. The miRNA detection reagent according to claim 7, It is characterized in that Also included are reverse transcriptase, buffer, DNA polymerase, and dNTPs.

9. A detection method based on the detection reagent of miRNA according to claim 7 or 8, It is characterized in that The following steps are involved: Extract RNA from the sample, perform reverse transcription reaction to reverse transcribe RNA into cDNA, and then perform real-time fluorescence quantitative PCR on the cDNA to obtain the relative expression level of miRNA; Preferably, the sample includes any one of a plasma sample and a cell sample.

10. A lung cancer resistance diagnosis kit, It is characterized in that A detection reagent comprising the miRNA according to claim 7 or 8.